SCN5A and glioma: Furthermore, the anti‐ELTD1 treatment worked to down‐regulate SCN5A, TRPM8 and BMP2, which were all shown to increase glioma cell proliferation, migration and invasion.48, 49, 50 Alkaline phosphatase (ALPL) is a stem cell marker, that is highly expressed around necrotic areas within the tumour, and high expression of ALPL and CD133 (another stem cell marker) has been associated with poor prognosis for patients.51 The mAb therapy against ELTD1 was successful in down‐regulating ALPL.